Achieve Life Sciences Q2 loss widens on warrant liabilities

Achieve Life Sciences

11/08/2026 13:39

Overview
US specialty pharma firm's Q2 net loss and loss per share missed analyst expectations
Q2 net loss includes $48.7 mln non-cash charge from warrant liabilities
Company closed private placement of up to $354 mln to fund cytisinicline program

Outlook
Achieve expects to resubmit cytisinicline NDA in Q4 2026, naming Adare as manufacturer
Company anticipates potential FDA approval in first half of 2027, with U.S. commercial launch to follow
Proceeds from $354 mln private placement expected to fund ORCA-V2 trial and commercialization

Result Drivers
NON-CASH WARRANT CHARGE - Q2 net loss included a $48.7 mln non-cash charge from change in fair value of warrant liabilities issued in private placement
ORGANIZATIONAL EXPANSION - Increased operating expenses attributed to hiring new executives, commercial team buildout, and board appointments
MANUFACTURING TRANSITION COSTS - Company advanced transition of finished drug product manufacturing to U.S.-based Adare Pharma Solutions, incurring related expenses

Company press release: ID:nGNXZNP6z

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Miss
$0.80
$0.16 (10 Analysts)
Q2 Net Loss
Miss
$74.77 mln
$13.25 mln (9 Analysts)
Q2 Income From Operations
Miss
-$18.39 mln
-$13.50 mln (8 Analysts)
Q2 Operating Expenses
 
$18.39 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Achieve Life Sciences, Inc. is $12.00, about 79.9% above its August 10 closing price of $6.67

Reuters Recommended Reads
Aug 10 - Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs
Aug 10 - Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)